MedTrace Logo

The RATIO: Registry of Infections and Lymphoma in Patients Treated With TNF-a Antagonists

NCT00224562 · Status: UNKNOWN · Type: OBSERVATIONAL

Last updated 2005-10-26

No results posted yet for this study

Summary

The RATIO registry is a French registry designed by a multidisciplinary group to collect data on opportunistic and severe bacterial infections and lymphoma in patients treated with TNF-a antagonists ( infliximab, etanercept and adalimumab). A total of 486 medical units in metropolitan France participate in the RATIO registry. All diagnosis are retained after validation by 2 qualified infectious disease or haematologist physicians (on the basis of the standardized case report form, the hospitalisation summary, and the microbiological and radiological results). Risk factors for developing these conditions when treated by TNF-a antagonists will be identified in a case control study. Incidence of these diseases will be calculated.

Conditions

Interventions

DRUG

TNF-alpha antagonists

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Xavier Mariette, MD PhD · Assistance Publique - Hôpitaux de Paris

  • Dominique Salmon, MD · Assistance Publique - Hôpitaux de Paris

  • Marc Lemann, MD · Assistance Publique - Hôpitaux de Paris

Eligibility

Min Age
0 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29

Countries

  • France

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00224562 on ClinicalTrials.gov